Why Acute Care Is Precision Medicine's Next Frontier
Precision medicine revolutionized oncology, but why has high-stakes acute care been left behind? Unlock this exclusive session with Prenosis CEO Dr. Bobby Reddy, Jr. to discover how a powerful convergence of AI, real-time biological profiling, and historic FDA momentum is finally transforming critical care.
Precision medicine transformed oncology by recognizing that patients who look clinically similar can have dramatically different underlying biology, and that treatment should follow the biology. Acute care for critical conditions such as sepsis, pneumonia, ARDS, acute heart failure, and acute kidney injury, has not benefited from the same revolution. In this session, Bobby Reddy Jr., PhD, CEO and co-founder of Prenosis, explores why that gap has persisted and how a convergence of AI, real-time data, and regulatory momentum is finally changing what's possible.
In this webinar with Dr. Bobby Reddy, Jr. and Healthcare Innovation’s Melinda Taschetta-Millane, viewers will learn:
Precision medicine transformed oncology by recognizing that patients who look clinically similar can have dramatically different underlying biology, and that treatment should follow the biology. Acute care for critical conditions such as sepsis, pneumonia, ARDS, acute heart failure, and acute kidney injury, has not benefited from the same revolution. In this session, Bobby Reddy Jr., PhD, CEO and co-founder of Prenosis, explores why that gap has persisted and how a convergence of AI, real-time data, and regulatory momentum is finally changing what's possible.
In this webinar with Dr. Bobby Reddy, Jr. and Healthcare Innovation’s Melinda Taschetta-Millane, viewers will learn:
- Why drug development for sepsis and other critical conditions has lagged, and how patient stratification is at the root of most trial failures.
- How FDA authorization of Sepsis ImmunoScore® signals a broader shift in how regulators are approaching AI diagnostics.
- The science behind the Prenosis precision medicine platform: from real-time biological profiling to smarter clinical trials and therapeutic matching.4.What the BARDA-funded respiratory illness study reveals about the platform's reach beyond sepsis.
- The near- and long-term vision for precision medicine in acute care, and what it will take to make it a reality.
Watch this On Demand Webinar now!
ผู้ให้บริการ: Healthcare Innovation | ระยะเวลา: 00:00 | ภาษา: อังกฤษ